ESR1 and breast carcinoma: A recent report indicated that inhibition of UCP-2 increased oxidative stress and sensitized breast cancer cells to tamoxifen treatment, suggesting UCP-2 as a new therapeutic target in estrogen receptor positive breast cancer [14].